CS 20AT04

Drug Profile

CS 20AT04

Alternative Names: CS 20 AT 04

Latest Information Update: 13 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CORESTEM
  • Developer CORESTEM; Hanyang University
  • Class Anti-inflammatories; Immunotherapies; Stem cell therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lupus nephritis

Most Recent Events

  • 30 May 2017 Phase-I clinical trials in Lupus nephritis in South Korea (IV) (NCT03174587)
  • 01 May 2015 Preclinical trials in Lupus nephritis in South Korea (IV) (NCT03174587)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top